Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity

Xing Wei, Yvonne Roettger, Bailin Tan, Yongzheng He, Richard Dodel, Harald Hampel, Gang Wei, Jillian Haney, Huiying Gu, Brian H. Johnstone, Junyi Liu, Martin Farlow, Yansheng Du

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Prion diseases are a group of rare, fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP C) into a self-replicating and proteinase K-resistant conformer, termed scrapie PrP (PrP Sc). Aggregates of PrP Sc deposited around neurons lead to neuropathological alterations. Currently, there is no effective treatment for these fatal illnesses; thus, the development of an effective therapy is a priority. PrP peptide-based ELISA assay methods were developed for detection and immunoaffinity chromatography capture was developed for purification of naturally occurring PrP peptide autoantibodies present in human CSF, individual donor serum, and commercial preparations of pooled intravenous immunoglobulin (IVIg). The ratio of anti- PrP autoantibodies (PrP-AA) to total IgG was ∼1:1200. The binding epitope of purified PrP-AA was mapped to an N-terminal region comprising the PrP amino acid sequence KTNMK. Purified PrP-AA potently blocked fibril formation by a toxic 21-amino acid fragment of the PrP peptide containing the amino acid alanine to valine substitution corresponding to position 117 of the full-length peptide (A117V). Furthermore, PrP-AA attenuated the neurotoxicity of PrP(A117V) and wildtype peptides in rat cerebellar granule neuron (CGN) cultures. In contrast, IgG preparations depleted of PrP-AA had little effect on PrP fibril formation or PrP neurotoxicity. The specificity of PrP-AA was demonstrated by immunoprecipitating PrP protein in brain tissues of transgenic mice expressing the human PrP(A117V) epitope and Sc237 hamster. Based on these intriguing findings, it is suggested that human PrP-AA may be useful for interfering with the pathogenic effects of pathogenic prion proteins and, thereby has the potential to be an effective means for preventing or attenuating human prion disease progression.

Original languageEnglish
Pages (from-to)12858-12866
Number of pages9
JournalJournal of Biological Chemistry
Volume287
Issue number16
DOIs
StatePublished - Apr 13 2012

Fingerprint

Prions
Autoantibodies
Anti-Idiotypic Antibodies
Peptides
Antibodies
Prion Diseases
Amino Acids
Neurons
Epitopes
Immunoglobulin G
PrPSc Proteins
Endopeptidase K
Peptide Fragments
Poisons
Intravenous Immunoglobulins
Valine
Chromatography
Protein C
Cricetinae
Neurodegenerative Diseases

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. / Wei, Xing; Roettger, Yvonne; Tan, Bailin; He, Yongzheng; Dodel, Richard; Hampel, Harald; Wei, Gang; Haney, Jillian; Gu, Huiying; Johnstone, Brian H.; Liu, Junyi; Farlow, Martin; Du, Yansheng.

In: Journal of Biological Chemistry, Vol. 287, No. 16, 13.04.2012, p. 12858-12866.

Research output: Contribution to journalArticle

Wei, X, Roettger, Y, Tan, B, He, Y, Dodel, R, Hampel, H, Wei, G, Haney, J, Gu, H, Johnstone, BH, Liu, J, Farlow, M & Du, Y 2012, 'Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity', Journal of Biological Chemistry, vol. 287, no. 16, pp. 12858-12866. https://doi.org/10.1074/jbc.M111.255836
Wei, Xing ; Roettger, Yvonne ; Tan, Bailin ; He, Yongzheng ; Dodel, Richard ; Hampel, Harald ; Wei, Gang ; Haney, Jillian ; Gu, Huiying ; Johnstone, Brian H. ; Liu, Junyi ; Farlow, Martin ; Du, Yansheng. / Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. In: Journal of Biological Chemistry. 2012 ; Vol. 287, No. 16. pp. 12858-12866.
@article{b0e1d51d94e2444d9a790a0c4a9199d8,
title = "Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity",
abstract = "Prion diseases are a group of rare, fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP C) into a self-replicating and proteinase K-resistant conformer, termed scrapie PrP (PrP Sc). Aggregates of PrP Sc deposited around neurons lead to neuropathological alterations. Currently, there is no effective treatment for these fatal illnesses; thus, the development of an effective therapy is a priority. PrP peptide-based ELISA assay methods were developed for detection and immunoaffinity chromatography capture was developed for purification of naturally occurring PrP peptide autoantibodies present in human CSF, individual donor serum, and commercial preparations of pooled intravenous immunoglobulin (IVIg). The ratio of anti- PrP autoantibodies (PrP-AA) to total IgG was ∼1:1200. The binding epitope of purified PrP-AA was mapped to an N-terminal region comprising the PrP amino acid sequence KTNMK. Purified PrP-AA potently blocked fibril formation by a toxic 21-amino acid fragment of the PrP peptide containing the amino acid alanine to valine substitution corresponding to position 117 of the full-length peptide (A117V). Furthermore, PrP-AA attenuated the neurotoxicity of PrP(A117V) and wildtype peptides in rat cerebellar granule neuron (CGN) cultures. In contrast, IgG preparations depleted of PrP-AA had little effect on PrP fibril formation or PrP neurotoxicity. The specificity of PrP-AA was demonstrated by immunoprecipitating PrP protein in brain tissues of transgenic mice expressing the human PrP(A117V) epitope and Sc237 hamster. Based on these intriguing findings, it is suggested that human PrP-AA may be useful for interfering with the pathogenic effects of pathogenic prion proteins and, thereby has the potential to be an effective means for preventing or attenuating human prion disease progression.",
author = "Xing Wei and Yvonne Roettger and Bailin Tan and Yongzheng He and Richard Dodel and Harald Hampel and Gang Wei and Jillian Haney and Huiying Gu and Johnstone, {Brian H.} and Junyi Liu and Martin Farlow and Yansheng Du",
year = "2012",
month = "4",
day = "13",
doi = "10.1074/jbc.M111.255836",
language = "English",
volume = "287",
pages = "12858--12866",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "16",

}

TY - JOUR

T1 - Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity

AU - Wei, Xing

AU - Roettger, Yvonne

AU - Tan, Bailin

AU - He, Yongzheng

AU - Dodel, Richard

AU - Hampel, Harald

AU - Wei, Gang

AU - Haney, Jillian

AU - Gu, Huiying

AU - Johnstone, Brian H.

AU - Liu, Junyi

AU - Farlow, Martin

AU - Du, Yansheng

PY - 2012/4/13

Y1 - 2012/4/13

N2 - Prion diseases are a group of rare, fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP C) into a self-replicating and proteinase K-resistant conformer, termed scrapie PrP (PrP Sc). Aggregates of PrP Sc deposited around neurons lead to neuropathological alterations. Currently, there is no effective treatment for these fatal illnesses; thus, the development of an effective therapy is a priority. PrP peptide-based ELISA assay methods were developed for detection and immunoaffinity chromatography capture was developed for purification of naturally occurring PrP peptide autoantibodies present in human CSF, individual donor serum, and commercial preparations of pooled intravenous immunoglobulin (IVIg). The ratio of anti- PrP autoantibodies (PrP-AA) to total IgG was ∼1:1200. The binding epitope of purified PrP-AA was mapped to an N-terminal region comprising the PrP amino acid sequence KTNMK. Purified PrP-AA potently blocked fibril formation by a toxic 21-amino acid fragment of the PrP peptide containing the amino acid alanine to valine substitution corresponding to position 117 of the full-length peptide (A117V). Furthermore, PrP-AA attenuated the neurotoxicity of PrP(A117V) and wildtype peptides in rat cerebellar granule neuron (CGN) cultures. In contrast, IgG preparations depleted of PrP-AA had little effect on PrP fibril formation or PrP neurotoxicity. The specificity of PrP-AA was demonstrated by immunoprecipitating PrP protein in brain tissues of transgenic mice expressing the human PrP(A117V) epitope and Sc237 hamster. Based on these intriguing findings, it is suggested that human PrP-AA may be useful for interfering with the pathogenic effects of pathogenic prion proteins and, thereby has the potential to be an effective means for preventing or attenuating human prion disease progression.

AB - Prion diseases are a group of rare, fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP C) into a self-replicating and proteinase K-resistant conformer, termed scrapie PrP (PrP Sc). Aggregates of PrP Sc deposited around neurons lead to neuropathological alterations. Currently, there is no effective treatment for these fatal illnesses; thus, the development of an effective therapy is a priority. PrP peptide-based ELISA assay methods were developed for detection and immunoaffinity chromatography capture was developed for purification of naturally occurring PrP peptide autoantibodies present in human CSF, individual donor serum, and commercial preparations of pooled intravenous immunoglobulin (IVIg). The ratio of anti- PrP autoantibodies (PrP-AA) to total IgG was ∼1:1200. The binding epitope of purified PrP-AA was mapped to an N-terminal region comprising the PrP amino acid sequence KTNMK. Purified PrP-AA potently blocked fibril formation by a toxic 21-amino acid fragment of the PrP peptide containing the amino acid alanine to valine substitution corresponding to position 117 of the full-length peptide (A117V). Furthermore, PrP-AA attenuated the neurotoxicity of PrP(A117V) and wildtype peptides in rat cerebellar granule neuron (CGN) cultures. In contrast, IgG preparations depleted of PrP-AA had little effect on PrP fibril formation or PrP neurotoxicity. The specificity of PrP-AA was demonstrated by immunoprecipitating PrP protein in brain tissues of transgenic mice expressing the human PrP(A117V) epitope and Sc237 hamster. Based on these intriguing findings, it is suggested that human PrP-AA may be useful for interfering with the pathogenic effects of pathogenic prion proteins and, thereby has the potential to be an effective means for preventing or attenuating human prion disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84859741481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859741481&partnerID=8YFLogxK

U2 - 10.1074/jbc.M111.255836

DO - 10.1074/jbc.M111.255836

M3 - Article

VL - 287

SP - 12858

EP - 12866

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 16

ER -